Today is the 17th World diabetes Day.

In the past decades, the incidence rate of diabetes is still on the rise worldwide. The prevalence of adult diabetes in China has risen to 11.2%, and the number of patients has reached 140 million. Although we have a deep understanding of many aspects of this disease, there are still many unsolved mysteries about the pathogenesis of diabetes.

The slogan of this year's World diabetes Day is "Know the risk, understand the response" - to understand the risk of suffering from type 2 diabetes, and ensure early diagnosis and timely treatment to reduce the risk of complications related to diabetes.

Professor Ji Linong, director of the Department of Endocrinology of Peking University People's Hospital, pointed out that type 2 diabetes is a chronic metabolic disease with highly heterogeneous etiology, involving multiple factors such as heredity, environment and lifestyle. Incidence rate is related to gene variation, biological pathway or mechanism, environment, obesity and other factors.

Therefore, the clinical treatment concept of diabetes has undergone several changes. A hundred years after insulin was used clinically, a series of drugs for diabetes treatment came out one after another: insulin and its analogues, biguanides, sulfonylureas, glinides α- There are 9 categories, including glycosidase inhibitors (AGI), thiazolidinediones (TZDs), dipeptidyl peptidase 4 inhibitors (DPP-4), sodium glucose co transporter 2 inhibitors (SGLT-2), and glucagon like peptide 1 receptor agonists (GLP-1).

Among the nine types of drugs mentioned above, dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), as a new type of hypoglycemic drug that has been clinically introduced in recent years, are hailed by clinical doctors as the "smartest hypoglycemic drug" due to their mechanism of action being consistent with the physiological regulation of blood sugar in the human body. Their clinical applications have been continuously increasing in recent years, and their position in domestic and international guidelines has become increasingly important.

DPP-4 inhibitors do not directly stimulate insulin, but act by inhibiting the catabolism of glucagon like peptide-1 (GLP-1) in the body. DPP-4 inhibitors can increase the levels of endogenous GLP-1 and glucose dependent insulin stimulating peptide (GIP), improving pancreatic islets β Cellular dysfunction, inhibition of pancreatic islets α Cells secrete glucagon, thereby promoting insulin secretion in a glucose concentration dependent manner, exerting a hypoglycemic effect, and not easily inducing hypoglycemia and weight gain. Meanwhile, as a once a day oral medication, it has good convenience and compliance.

In the next three years, the international market size of DPP-4 inhibitors will reach 19.2 billion US dollars, and the domestic market size will also exceed 30 billion RMB. Therefore, DPP-4 inhibitors are a must-have in the eyes of major pharmaceutical companies, and the domestic market is hot.

Shengshi Taike independently developed a new generation of highly selective DPP-4 inhibitor, Sengliptin (formerly known as Sengliptin), and its clinical results show that compared with similar drugs already on the market, its "half effect" treatment effect is expected to become the best hypoglycemic drug in the class. Even more precious is that its safety further solves the common adverse reactions in products already on the market.

At present, adverse reactions such as nasopharyngitis, headache, and upper respiratory tract infections are commonly present in DPP-4 inhibitors that have been marketed. In the comparison between the 100mg dose group (high-dose group) and the placebo group in the following 28 weeks, Sengliptin improved the above issues with high quality. According to publicly available clinical data, there have been 4% -7% incidence of adverse reactions such as nasopharyngitis and headache in all marketed products, while Sengliptin has not experienced any of these adverse reactions; In terms of adverse reactions to upper respiratory tract infections, all marketed products have an incidence rate of 3% -8%, while Sengliptin has an incidence rate of less than 0.5%, which is similar to that of the placebo group.

The reason for this can be attributed to Sengliptin's "source innovation". The new molecular structure of Sengliptin designed by the company based on an integrated drug research and development platform has better selectivity and specificity, thus demonstrating the most reassuring safety for patients in clinical trials.

Shengshi Taike truly achieves the goal of using "source innovation" to solve unsatisfied clinical pain points, bringing "stable" happiness to the general public.